Skip to content

Medivir AB Sustainability Reports

Medivir AB develops innovative therapies targeting diseases with high unmet medical needs, with a primary focus on oncology. Its lead drug candidates are designed to treat advanced liver cancer and other rare clinical conditions.

Sector: Manufacturing

Country: Sweden

Exchange: Nasdaq Stockholm

LEI: 549300VWDGUX0WMJ1T79

FIGI: BBG001S9BMP9

25 reports from 2012 to 2025